Your browser doesn't support javascript.
loading
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Annala, Matti; Vandekerkhove, Gillian; Khalaf, Daniel; Taavitsainen, Sinja; Beja, Kevin; Warner, Evan W; Sunderland, Katherine; Kollmannsberger, Christian; Eigl, Bernhard J; Finch, Daygen; Oja, Conrad D; Vergidis, Joanna; Zulfiqar, Muhammad; Azad, Arun A; Nykter, Matti; Gleave, Martin E; Wyatt, Alexander W; Chi, Kim N.
Affiliation
  • Annala M; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Vandekerkhove G; Faculty of Medicine and Life Sciences and Biomeditech Institute, University of Tampere, Tampere, Finland.
  • Khalaf D; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Taavitsainen S; British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada.
  • Beja K; Faculty of Medicine and Life Sciences and Biomeditech Institute, University of Tampere, Tampere, Finland.
  • Warner EW; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Sunderland K; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Kollmannsberger C; British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada.
  • Eigl BJ; British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada.
  • Finch D; British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada.
  • Oja CD; British Columbia Cancer Agency, Southern Interior Centre, Kelowna, British Columbia, Canada.
  • Vergidis J; British Columbia Cancer Agency, Fraser Valley Centre, Vancouver, British Columbia, Canada.
  • Zulfiqar M; British Columbia Cancer Agency, Vancouver Island Centre, Victoria, British Columbia, Canada.
  • Azad AA; British Columbia Cancer Agency, Abbotsford Centre, Vancouver, British Columbia, Canada.
  • Nykter M; Monash University, Monash, Australia.
  • Gleave ME; Faculty of Medicine and Life Sciences and Biomeditech Institute, University of Tampere, Tampere, Finland.
  • Wyatt AW; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Chi KN; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. awyatt@prostatecentre.com kchi@bccancer.bc.ca.
Cancer Discov ; 8(4): 444-457, 2018 04.
Article in En | MEDLINE | ID: mdl-29367197
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylthiohydantoin / Prostatic Neoplasms / BRCA2 Protein / Ataxia Telangiectasia Mutated Proteins / Circulating Tumor DNA / Androstenes / Mutation / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Aged / Humans / Male Language: En Journal: Cancer Discov Year: 2018 Document type: Article Affiliation country: Canada
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylthiohydantoin / Prostatic Neoplasms / BRCA2 Protein / Ataxia Telangiectasia Mutated Proteins / Circulating Tumor DNA / Androstenes / Mutation / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Aged / Humans / Male Language: En Journal: Cancer Discov Year: 2018 Document type: Article Affiliation country: Canada